Oxford-based AI technology company Sensyne Health has launched a new smartphone software application that uses deep machine learning to automate the accurate reading and big data analysis of lateral flow diagnostic tests.
The MagnifEye application was built in response to the demand generated by the COVID-19 pandemic for the accurate and standardised reading of lateral flow tests used for disease surveillance across large populations and the big data analysis results in real time.
MagnifEye can be trained to read and analyse individual lateral flow tests and has applications in human and animal health, including cancer, infectious diseases and fertility, as well as plant pathogen and environmental testing.
It can be used as a standalone app or incorporated into third part web or native software apps.
Lord Paul Drayson, the firm’s CEO, said: “Applying clinical AI to medical imaging has been an important R&D focus for Sensyne since formation and the company has developed world-class deep learning AI capabilities in this area and has a collaboration with Bayer in the field of machine vision.
“Diagnostic testing has seen rapid progress over the past year, accelerated by responses to the COVID-19 pandemic. We have been working on developing a general capability to automate the reading of lateral flow tests in response to demand from commercial test manufacturers and healthcare providers.
“We look forward to working with these potential partners to apply this technology as rapidly as possible.”
Sign up to our newsletter